CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer

Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

Understanding patient expectations and clinicians' goals in favourable risk aRCC patients

STRIDE ± lenvatinib plus TACE improves outcomes in unresectable early-to-intermediate HCC

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer